New drug targets tough cancers in early trial
NCT ID NCT06238479
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called LY4101174 in people with advanced solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety, find the right dose, and see if it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Austin Health
Heidelberg, 3084, Australia
-
CHU Strasbourg-Hautepierre
Strasbourg, 67098, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Emory University
Atlanta, Georgia, 30322, United States
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Virgen Del Rocio
Seville, 41013, Spain
-
Hunan Cancer Hospital
Changsha, 410013, China
-
Icon Cancer Centre Kurralta Park
Kurralta Park, 5037, Australia
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, 13273, France
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chūōku, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, 277-8577, Japan
-
Peking University First Hospital
Beijing, 100034, China
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Shanghai East Hospital
Shanghai, 200433, China
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229-3307, United States
-
The Cancer Institute Hospital of JFCR
Kōtō City, 135-8550, Japan
-
UT Southwestern Medical Center
Dallas, Texas, 75390-8884, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.